A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Trial Profile

A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Vosaroxin (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Jun 2016 Results (n=63) published in a Sunesis Pharmaceuticals media release.
    • 20 May 2016 According to a Sunesis Pharmaceuticals media release, results of this trial will be presented at the 21st Congress of the European Hematology Association (EHA) in June 2016. Sunesis is following regulatory approval in Europe for vosaroxin for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 years and older.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top